FilingReader Intelligence

Xianju Pharmaceutical fined for monopoly violations

May 5, 2025 at 05:10 PM UTCBy FilingReader AI

Zhejiang Xianju Pharmaceutical (SZSE:002332) has announced it received an administrative penalty decision from the Tianjin Market Supervision and Administration Commission regarding violations of China's Anti-Monopoly Law. The commission determined that the company engaged in monopolistic agreements with competitors to manipulate and fix the price of dexamethasone sodium phosphate API.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Zhejiang Xianju Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →